Authors: Youhanna Al-Tawil, MD; Erika Ryan, DCN, RD, CDN; PJ Patterson, Madden Wilson, RDN, LDN, CNSC; Vanessa Millovich, DCN, MS, RDN, CNSC
Abstract presented at North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) 2022 and published in the supplement of the Journal of Pediatric Gastroenterology and Nutrition (JPGN).
Awarded a NASPGHAN Poster of Distinction
The purpose of this study was to assess the growth and tolerance of pediatric patients who transitioned from a hypoallergenic formula to a pea protein plant-based formula (PPPBF). This was a retrospective cohort study using an online survey completed between May 12 to May 26, 2022. Clinicians entered deidentified data for pediatric patients ages 1 to 18 years old who transitioned to Kate Farms Pediatric Peptide 1.0 (46.6%), Pediatric Peptide 1.5 (19.2%), or Pediatric Standard 1.2 (34.2%).
Transition from a hypoallergenic formula to a PPPBF resulted in improved or stable GI tolerance, weight gain or stability, and demonstrated adherence and safety in pediatric patients (n=73):
94.5% tolerated better or the same
38.4% (n=28) had improved GI tolerance†
56.2% had no change in GI tolerance
94.5% gained or maintained weight
64.4% gained weight
30.1% maintained weight
94.5% adhered to treatment plan‡
98.6% had no adverse reaction§
* Research funding provided by Kate Farms, Inc.
† Clinicians reported improvement in abdominal pain, reflux, diarrhea, constipation, bloating, nausea, vomiting, and/or early satiety.
‡ Adherence defined as receiving at least 75% of the prescribed amount.
§ No adverse reaction was the measure for safety. One patient was noted to have diarrhea.
1. Al-Tawil Y, Ryan E, Patterson PJ, Wilson M, Millovich V. Growth and tolerance of pediatric patients transitioned from a hypoallergenic formula to a pea-protein plant-based formula. JPGN.2022;75(S1):S482-483.